Please login to the form below

Not currently logged in
Email:
Password:

Evan Lippman joins Aileron Therapeutics

He has experience at EMD Serono, Pfizer and AstraZeneca
Evan Lippman joins Aileron Therapeutics

Aileron Therapeutics has added to its senior team with the appointment of Evan Lippman as its first chief financial and business officer.

The addition comes as the US biopharma prepares to advance its lead oncology candidate ALRN-6924 into clinical trials.

In Lippman Aileron gains the expertise of a man with great experience in life sciences. Most recently Lippman help a senior VP role at EMD Serono heading the strategy for its US neurology franchise.

Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development at the same company.

Lippman's other big pahrma experience includes a period at Pfizer as executive director, worldwide business development and strategic planning.

12th January 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...